A
RARE icon

AlphaQuest’s Ultragenyx Pharmaceutical RARE Stock Holding History

AlphaQuest’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,859
Closed -$135K – 1598
2025
Q4 		$135K Buy
5,859
+5,275
+903% +$173K 0.01% 1624
2025
Q3 		$17.6K Sell
584
-7,058
-92% -$212K ﹤0.01% 2106
2025
Q2 		$278K Sell
7,642
-3,277
-30% -$118K 0.03% 927
2025
Q1 		$395K Buy
10,919
+2,752
+34% +$114K 0.04% 630
2024
Q4 		$344K Buy
8,167
+6,022
+281% +$299K 0.05% 642
2024
Q3 		$119K Buy
+2,145
New +$109K 0.01% 1245
2024
Q2 		– Sell
-11,522
Closed -$538K – 1827
2024
Q1 		$538K Buy
+11,522
New +$544K 0.09% 346

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

AlphaQuest's RARE Position: Q1 2026 in Review

AlphaQuest sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2026, closing a stake of 5,859 shares — an estimated $135K sold.

AlphaQuest first reported a position in RARE in Q1 2024 and held it in 7 quarters. The position peaked at $538K in Q1 2024. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • AlphaQuest reported no remaining Ultragenyx Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 5,859 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $135K.
  • AlphaQuest first reported a position in Ultragenyx Pharmaceutical in Q1 2024 and held it in 7 quarters.
  • AlphaQuest's Ultragenyx Pharmaceutical position peaked at $538K in Q1 2024.
  • 296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.